Literature DB >> 11830512

Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.

Tine Van de Sande1, Ellen De Schrijver, Walter Heyns, Guido Verhoeven, Johannes V Swinnen.   

Abstract

One of the most common molecular changes in cancer cells is the overexpression of fatty acid synthase (FAS), a key metabolic enzyme catalyzing the terminal steps in the synthesis of long chain saturated fatty acids. As part of our efforts to elucidate the mechanisms responsible for FAS overexpression, we have addressed the question whether overexpression of FAS may be linked to the frequently observed inactivation of PTEN and subsequent activation of the phosphatidylinositol 3'-kinase (PI3k) pathway. Using LNCaP prostate cancer cells as an experimental paradigm of FAS-overexpressing PTEN-null cancer cells, we demonstrate that LY294002, an inhibitor of the PI3k pathway causes a dramatic decrease in FAS protein expression. Smaller but still substantial effects are seen at the FAS mRNA level and at the level of transcriptional activity of FAS promoter-reporter constructs. Consistent with these findings, reintroduction of PTEN results in decreased levels of FAS expression in a manner that is dependent on its lipid phosphatase activity. In support of a role for Akt/protein kinase B as a downstream effector, cotransfection of constitutively active Akt1/protein kinase B alpha abrogates the inhibitory effects of PTEN expression and restores FAS promoter activity. Taken together, these results demonstrate that inactivation of PTEN and subsequent activation of the PI3k/Akt kinase pathway may play an important role in the overexpression of the FAS protein in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830512

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

1.  Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.

Authors:  Abir Mukherjee; Jinhua Wu; Suzanne Barbour; Xianjun Fang
Journal:  J Biol Chem       Date:  2012-06-03       Impact factor: 5.157

2.  Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.

Authors:  Vanessa Fritz; Zohra Benfodda; Geneviève Rodier; Corinne Henriquet; François Iborra; Christophe Avancès; Yves Allory; Alexandre de la Taille; Stéphane Culine; Hubert Blancou; Jean Paul Cristol; Françoise Michel; Claude Sardet; Lluis Fajas
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

3.  SLUG is a direct transcriptional repressor of PTEN tumor suppressor.

Authors:  Berna Uygur; Katrina Abramo; Evgenia Leikina; Calvin Vary; Lucy Liaw; Wen-Shu Wu
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

4.  Activated α2-macroglobulin binding to human prostate cancer cells triggers insulin-like responses.

Authors:  Uma Kant Misra; Salvatore Vincent Pizzo
Journal:  J Biol Chem       Date:  2015-02-26       Impact factor: 5.157

Review 5.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

6.  Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.

Authors:  Debasmita Roy; Dirk P Dittmer
Journal:  Am J Pathol       Date:  2011-08-03       Impact factor: 4.307

Review 7.  Polyunsaturated fatty acid metabolism in prostate cancer.

Authors:  Isabelle M Berquin; Iris J Edwards; Steven J Kridel; Yong Q Chen
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

8.  Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death.

Authors:  Joy L Little; Frances B Wheeler; Constantinos Koumenis; Steven J Kridel
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

9.  Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells.

Authors:  Lakshmi Reddy Bollu; Jiangong Ren; Alicia Marie Blessing; Rajasekhara Reddy Katreddy; Guang Gao; Lei Xu; Jinrong Wang; Fei Su; Zhang Weihua
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Emanuel N Husu; Costas Pitsillides; Steven Vesole; Abdel Kareem Azab; Feda Azab; Molly Melhem; Hai T Ngo; Phong Quang; Patricia Maiso; Judith Runnels; Mei-Chih Liang; Kwok-Kin Wong; Charles Lin; Irene M Ghobrial
Journal:  Blood       Date:  2009-11-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.